Emerging Areas in Treatment
Researchers are always searching for new and better ways to treat breast cancer.
Advances over the last 40 years have increased survival and improved the quality of life for people diagnosed with breast cancer.
Treatments now under study should continue this progress into the future.
Our commitment to research
At Susan G. Komen®, we are committed to saving lives by meeting the most critical needs in our communities and investing in breakthrough research to prevent and cure breast cancer. Our Research Program is an essential driving force for achieving this mission.
Since our inception in 1982, Komen has provided funding to support research grants that have greatly expanded our knowledge of breast cancer and helped us understand that breast cancer is not just a single disease but many diseases, unique to each individual.
Going forward, our commitment to research will contribute significantly to our ability to achieve our Bold Goal of reducing the current number of breast cancer deaths in the U.S. by 50 percent.
To date, Komen has provided more than $1 billion to researchers in 47 states, the District of Columbia and 24 countries to support research that has resulted in a better understanding of breast cancer; earlier detection; personalized, less invasive treatments for what was once a “one-treatment-fits-all” disease; and improvements in both quality of life and survival rates.
Learn more about our continuing investment in research and the exciting research that we are funding, because nothing would make us happier than ending breast cancer forever.
Emerging areas in treatment
Perhaps the most promising new treatments are targeted therapies. Unlike many standard treatments, targeted therapies attack specific cancer cells and leave healthy cells alone. So, they may help limit side effects and improve survival.
Learn about new therapies under study, including immunotherapy, in the following areas:
- Radiation therapy
- Chemotherapy, hormone therapy and other drug therapies
- Ductal carcinoma in situ (DCIS)
- Metastatic breast cancer
Research is ongoing to improve all areas of treatment for breast cancer.
New therapies are being studied in clinical trials. The results of these studies will decide whether these therapies become part of standard care.
After discussing the benefits and risks with your health care provider, we encourage you to consider joining a clinical trial.
Susan G. Komen® Breast Cancer Clinical Trial Information Helpline
If you or a loved one needs information or resources about clinical trials, call our Clinical Trial Information Helpline at 1-877 GO KOMEN (1-877- 465- 6636) or email email@example.com.
The helpline offers breast cancer clinical trial education and support, such as:
BreastCancerTrials.org in collaboration with Susan G. Komen® offers a custom matching service to help find clinical trials that fit your needs.
Learn more about clinical trials.
Read our perspective on clinical trials.*
* Please note, the information provided within Komen Perspectives articles is only current as of the date of posting. Therefore, some information may be out of date.
TOOLS & RESOURCES